Delighted to share our Cancer Cell paper published today, co-authored by Dr. Alexander Biederstädt @ABiederstadt_MD and Dr. Rafet Basar @rftbsr9 reporting the first genome-wide CRISPR screen in primary cord blood NK and CAR NK cells. We identify key genetic checkpoints including MED12, ARIH2 and CCNC and show that their deletion enhances CAR NK cell antitumor activity in multiple tumor models. Congratulations to Alex for leading this study, to Rafet for his major contributions, and to all of our collaborators and co-authors for making this work possible. cell.com/cancer-cell/fulltex… @MDAndersonNews @kchenken #NK #CRISPR #immunotherapy #endcancer

Results from a study open new avenues for discovering approaches to enhance the antitumor activity of CAR NK cell therapies against multiple cancer types via a comprehensive CRISPR discovery platform optimized for primary human NK cells. Read more: spr.ly/6018fxaTs @lab_rezvani #EndCancer

New #JITC article: Histologic and immune characterization of cutaneous immune-related adverse events induced by immune checkpoint inhibitors bit.ly/4oD8LzK @AnishaPatelMD @cara_haymaker @ANaingMD @MDAndersonNews

Please check out our paper published today in Nature that identifies CREM as a key checkpoint limiting CAR NK cell function.CRISPR knockout of CREM significantly enhanced anti-tumor activity, implicating a broader role in NK cell regulation. Huge congrats to @hindrafei and our

Now online in @CD_AACR: Depletion of Effector Regulatory T Cells Associates with Major Response to Induction Dual Immune Checkpoint Blockade - by Xianli Jiang, @kchenken, Maura Gillison, and colleagues doi.org/10.1158/2159-8290.CD… @MDAndersonNews

A statistical approach for systematic identification of transition cells from scRNA-seq data dlvr.it/TGf0vn

New paper from our group in @Nature by @YiyunLin_YL @junkewang @KaileWang and team reporting the unexpected discovery of aneuploid epithelial cells (3%) in normal breast tissues from healthy women raising the question of when is cancer really cancer? nature.com/articles/s41586-0…

Menin inhibition is a standard of care! FDA approval of revumenib!! So happy to see that the benefit witnessed in patients on study is leading to a medicine to all who need it. Ready to forj ahead with more to come! ;)

With the goal of advancing cell therapies for patients like JC Cox, MD Anderson has launched the Institute for Cell Therapy Discovery & Innovation. Read more: brnw.ch/21wOup7 @lab_rezvani #EndCancer

Excited to share our manuscript published in @ScienceTM, where we describe a novel NK immune evasion strategy in AML. We found that #BATF is a key transcription factor driving epigenetic reprogramming in NK cells in AML. This TF is induced by the canonical TGF-β/SMAD pathway and leads to persistent NK cell dysfunction. This dysfunction can be prevented by deleting BATF or TGFBR2 upstream, but once established, it cannot be reversed. Designed to overcome epigenetic scarring, we look forward to bringing this novel CAR-NK cell approach to the clinic to improve outcomes for AML patients. @mdandersonnews @lab_rezvani @bijender2050 #AML #NK #CRISPR #epigenetics #BATF